Drugs / 5-Methyltetrahydrofolate
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05366933 | Aug 2022 → Jul 2027 expected | optic nerve disorder | National Aeronautics and Space Administration (NASA) | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06930144 | Apr 2025 → Apr 2026 overdue | type 1 diabetes mellitus | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-methyltetrahydrofolate | “Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin” NCT05366933 ↗1“5-Methyltetrahydrofolate (5-MTHF) can prevent oxidative loss of” PMID 37482222 ↗ Jul 2023 |
| Known as | 5-MTHF | “5-Methyltetrahydrofolate (5-MTHF) can prevent oxidative loss of” PMID 37482222 ↗ Jul 2023 |
| Modality | Other / unclassified | “daily nutraceutical supplement containing bioactive B vitamins” NCT05366933 ↗ |
| Route | Oral | “Daily oral intake of active folate 800ug combined with basic diabetic treatment” NCT06930144 ↗ |